SymPhysis Medical

Executive Summary

SymPhysis Medical is an Ireland-based medical device company founded in 2016, focused on improving the quality of life for patients with chronic conditions, particularly malignant pleural effusion (MPE). Its flagship product, releaze™, is an advanced indwelling pleural catheter that features intuitive one-touch control and a novel port design, offering a significant improvement over existing drainage solutions. MPE is a common and debilitating complication in advanced cancers, affecting approximately 150,000 patients annually in the US and Europe. Current catheters often require manual drainage and carry infection risks; releaze™ aims to simplify management, reduce hospital visits, and enhance patient autonomy. The company's technology positions it strongly in the growing interventional pulmonology market, with potential for rapid adoption if approved. SymPhysis Medical has likely conducted preclinical studies and is progressing toward regulatory submissions. With a lean operations model based in Galway's medtech cluster, the company is poised for strategic partnerships or funding to support clinical trials and commercialization. The unique one-touch mechanism and port-based system differentiate it from competitors like Rocket Medical and AngioDynamics. If successful, releaze™ could become the standard of care for MPE management, driving significant value for investors and patients alike.

Upcoming Catalysts (preview)

• Q3 2026Completion of CE Mark Submission70% success
• Q2 2026Series A Funding Round Close60% success
• TBDPublication of Initial Clinical Data50% success